Search

Your search keyword '"Fofana, Thierno Oumar"' showing total 12 results
Start Over Author "Fofana, Thierno Oumar"
12 results on '"Fofana, Thierno Oumar"'

1. rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l’essai proches)

Author

Conall H. Watson, Pierre-Stéphane Gsell, Yper Hall, Anton Camacho, Ximena Riveros, Godwin Enwere, Andrea Vicari, Séverine Danmadji Nadlaou, Alhassane Toure, Ismaila M. Sani, Abdourahamane Diallo, Cece Kolie, Sophie Duraffour, Kékoura Ifono, Andre Maomou, Kassie Dore, Honora A. Djidonou, Aminata Bagayoko, Philos P. Damey, Mabetty Nancy Camara, Fatoumata Battouly Diallo, Fofana Thierno Oumar, Kalidou Toure, Mohamed Lamine Diaby, Lansana Sylla, Doussou Conde, Ibrahima Lansana Kaba, Tom Tipton, Rosalind M. Eggo, Michael Marks, Chrissy H. Roberts, Thomas Strecker, Stephan Günther, Sakoba Keita, W. John Edmunds, Miles W. Carroll, and Ana Maria Henao-Restrepo

Subjects
Ebola virus disease, Ebola, Vaccine, RVSV-ZEBOV, Safety, Immunogenicity, Medicine
Abstract

Abstract Background Zaire Ebolavirus disease (EVD) outbreaks can be controlled using rVSV-ZEBOV vaccination and other public health measures. People in high-risk areas may have pre-existing antibodies from asymptomatic Ebolavirus exposure that might affect response to rVSV-ZEBOV. Therefore, we assessed the impact pre-existing immunity had on post-vaccination IgG titre, virus neutralisation, and reactogenicity following vaccination. Methods In this prospective cohort study, 2115 consenting close contacts (“proches”) of EVD survivors were recruited. Proches were vaccinated with rVSV-ZEBOV and followed up for 28 days for safety and immunogenicity. Anti-GP IgG titre at baseline and day 28 was assessed by ELISA. Samples from a representative subset were evaluated using live virus neutralisation. Results Ten percent were seropositive at baseline. At day 28, IgG in baseline seronegative (GMT 0.106 IU/ml, 95% CI: 0.100 to 0.113) and seropositive (GMT 0.237 IU/ml, 0.210 to 0.267) participants significantly increased from baseline (both p

Published
2024
Full Text
View/download PDF

3. Rvsv-Zebov Vaccination in People with Pre-Existing Immunity to Ebolavirus: An Open-Label Safety and Immunogenicity Study in Guinean Communities Affected by Ebola Virus Disease (L’Essai Proches)

Author

Watson, Conall H., primary, Gsell, Pierre-Stéphane, additional, Hall, Yper, additional, Camacho, Anton, additional, Riveros, Ximena, additional, Enwere, Godwin, additional, Vicari, Andrea, additional, Nadlaou, Séverine Danmadji, additional, Toure, Alhassane, additional, Sani, Ismaila M., additional, Diallo, Abdourahamane, additional, Barry, Aboubacar, additional, Kolie, Cece, additional, Duraffour, Sophie, additional, Maomou, Andre, additional, Dore, Kassie, additional, Djidonou, Honora A., additional, Bagayoko, Aminata, additional, Damey, Philos P., additional, Camara, Mabetty, additional, Diallo, Fatoumata, additional, Fofana, Thierno Oumar, additional, Toure, Kalidou, additional, Diaby, Mohamed, additional, Sylla, Lansana, additional, Conde, Doussou, additional, Kaba, Ibrahima Lansana, additional, Tipton, Tom, additional, Eggo, Rosalind M., additional, Marks, Michael, additional, Roberts, Chrissy H., additional, Strecker, Thomas, additional, Günther, Stephan, additional, Keita, Sakoba, additional, Edmunds, W. John, additional, Carroll, Miles W., additional, and Henao Restrepo, Ana Maria, additional

Published
2024
Full Text
View/download PDF

5. Quantifying the value of viral genomics when inferring who infected whom in the 2014–16 Ebola virus outbreak in Guinea

Author

Robert, Alexis, primary, Tsui Lok Hei, Joseph, additional, Watson, Conall H, additional, Gsell, Pierre-Stéphane, additional, Hall, Yper, additional, Rambaut, Andrew, additional, Longini, Ira M, additional, Sakoba, Keïta, additional, Kucharski, Adam J, additional, Touré, Alhassane, additional, Danmadji Nadlaou, Sévérine, additional, Saidou Barry, Mamadou, additional, Fofana, Thierno Oumar, additional, Lansana Kaba, Ibrahima, additional, Sylla, Lansana, additional, Diaby, Mohamed Lamine, additional, Soumah, Ousmane, additional, Diallo, Abdourahime, additional, Niare, Amadou, additional, Diallo, Abdourahamane, additional, Eggo, Rosalind M, additional, Caroll, Miles W, additional, Henao-Restrepo, Ana Maria, additional, Edmunds, W John, additional, and Hué, Stéphane, additional

Published
2023
Full Text
View/download PDF

10. Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report

Author

William John Edmunds, Ira M. Longini, Abdourahmane Diallo, Thomas Mauget, Andrea S. Vicari, Abdourahamane Diallo, Diakite Mory, Djidonou A. Honora, Conall H. Watson, Ximena Riveros, Mosoka Fallah, Aminata Bagayoko, Godwin Enwere, Anton Camacho, Adam J. Kucharski, Natalie E. Dean, Fofana Thierno Oumar, Séverine Danmadji Nadlaou, Alhassane Toure, Elizabeth S. Higgs, Moussa Doumbia, Sakoba Keita, Ana Maria Henao-Restrepo, Pierre Stéphane Gsell, and Marie Paule Kieny

Subjects
Adult, Male, 0301 basic medicine, Pediatrics, medicine.medical_specialty, Adolescent, Health Personnel, medicine.disease_cause, Article, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Informed consent, Occupational Exposure, medicine, Humans, 030212 general & internal medicine, Ebola Vaccines, Child, Adverse effect, Ebola virus, Ebola vaccine, business.industry, Vaccination, Outbreak, Hemorrhagic Fever, Ebola, Virology, Clinical trial, 030104 developmental biology, Infectious Diseases, Expanded access, Female, Guinea, business
Abstract

BACKGROUND: In March, 2016, a flare-up of Ebola virus disease was reported in Guinea, and in response ring vaccination with the unlicensed rVSV-ZEBOV vaccine was introduced under expanded access, the first time that an Ebola vaccine has been used in an outbreak setting outside a clinical trial. Here we describe the safety of rVSV-ZEBOV candidate vaccine and operational feasibility of ring vaccination as a reactive strategy in a resource-limited rural setting. METHODS: Approval for expanded access and compassionate use was rapidly sought and obtained from relevant authorities. Vaccination teams and frozen vaccine were flown to the outbreak settings. Rings of contacts and contacts of contacts were defined and eligible individuals, who had given informed consent, were vaccinated and followed up for 21 days under good clinical practice conditions. FINDINGS: Between March 17 and April 21, 2016, 1510 individuals were vaccinated in four rings in Guinea, including 303 individuals aged between 6 years and 17 years and 307 front-line workers. It took 10 days to vaccinate the first participant following the confirmation of the first case of Ebola virus disease. No secondary cases of Ebola virus disease occurred among the vaccinees. Adverse events following vaccination were reported in 47 (17%) 6-17 year olds (all mild) and 412 (36%) adults (individuals older than 18 years; 98% were mild). Children reported fewer arthralgia events than adults (one [ INTERPRETATION: The results show that a ring vaccination strategy can be rapidly and safely implemented at scale in response to Ebola virus disease outbreaks in rural settings. FUNDING:WHO, Gavi, and the World Food Programme.

Published
2017
Full Text
View/download PDF

11. COVID-19 vaccine equity: a health systems and policy perspective.

Author

Van De Pas, Remco, Widdowson, Marc-Alain, Ravinetto, Raffaella, N Srinivas, Prashanth, Ochoa, Theresa J., Fofana, Thierno Oumar, and Van Damme, Wim

Subjects
COVID-19 vaccines, HEALTH equity, VACCINATION, COVID-19 pandemic, TECHNOLOGY transfer
Abstract

The global COVID-19 vaccine rollout has highlighted inequities in the accessibility of countries to COVID-19 vaccines. Populations in low- and middle-income countries have found it difficult to have access to COVID-19 vaccines. This perspective provides analyses on historical and contemporary policy trends of vaccine development and immunization programs, including the current COVID-19 vaccination drive, and governance challenges. Moreover, we also provide a comparative health system analysis of the COVID-19 vaccine deployment in some countries from different continents. It recommends that the international Access to COVID-19 Tools Accelerator (ACT-A) partnership requires a strong governance mechanism and urgent financial investment. All WHO member states should agree on technology transfer and voluntary license-sharing via a commonly governed technology access pool and supported by a just Intellectual Property regime. Contextualized, dynamic understandings and country-specific versions of health systems strengthening are needed to improve vaccine equity in a sustainable matter. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

12. Determinants of Transmission Risk During the Late Stage of the West African Ebola Epidemic

Author

Robert, Alexis, primary, Edmunds, W John, additional, Watson, Conall H, additional, Henao-Restrepo, Ana Maria, additional, Gsell, Pierre-Stéphane, additional, Williamson, Elizabeth, additional, Longini, Ira M, additional, Sakoba, Keïta, additional, Kucharski, Adam J, additional, Touré, Alhassane, additional, Nadlaou, Sévérine Danmadji, additional, Diallo, Boubacar, additional, Barry, Mamamdou Saidou, additional, Fofana, Thierno Oumar, additional, Camara, Louceny, additional, Kaba, Ibrahima Lansana, additional, Sylla, Lansana, additional, Diaby, Mohamed Lamine, additional, Soumah, Ousmane, additional, Diallo, Abdourahime, additional, Niare, Amadou, additional, Diallo, Abdourahmane, additional, and Eggo, Rosalind M, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results